About

Dr. Wohl is a physician-clinical researcher and clinician with a career dedicated to the study and treatment of emerging infectious diseases. Prior to 2014, his clinical and research activities were almost exclusively focused on the care of people with HIV infection and HIV-related patient-oriented research. He leads a large NIAID-supported HIV Clinical Research Site (CRS) at UNC-Chapel Hill and serves as Co-PI for the UNC Global Clinical Trials Research Unit (CTU), which includes sites in North Carolina, Malawi, and Vietnam. With the Ebola virus disease outbreak in West Africa in 2014, he expanded his work to other emerging infectious diseases including Ebola and Lassa fever, and with the pandemic, SARS-CoV-2. Dr. Wohl’s interest in viral hemorrhagic fevers led to his co-founding and co-directing the UNC Project-Liberia and the establishment of its two productive research sites in this West African nation.

In the news

• 

  Study Warns of Underrecognized Lassa Fever Threat with Global Implications

  Chapel Hill, NC—A new study led by researchers at the Institute for Global Health and Infectious Diseases at the University of North Carolina School of Medicine in Chapel Hill shows an urgent need for improved detection and treatment of Lassa fever, published in The Lancet Infectious Diseases. Lassa fever–a severe Ebola-like illness designated by the … Read more

• 

  American’s Response to COVID – Panel Discussion With David Wohl

  The UNC School of Civic Life and Leadership’s Program for Public Discourse held the panel discussion “America’s Response to Covid” on Dec. 2. What can we learn from America’s response to the COVID-19 pandemic?  How should policymakers deal with future pandemics?  In a recent book co-authored with Stephen Macedo, Princeton professor Frances Lee argues that … Read more

• 

  Webinar: Global Threats, Local Actions

  “We at the Institute for Global Health and infectious diseases are a large community of multi-disciplinary investigators,” said Sonia Napravnik, PhD, in her webinar welcome message during University Research Week. “And essentially, we all focus on improving health globally and locally, here in North Carolina and across the US.” “Our focus is really on research, … Read more

• 

  Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn’s Disease

  Higher drug levels and combination therapy with low-dose oral methotrexate (LD-MTX) may reduce anti-tumor necrosis factor (TNF) treatment failure in pediatric Crohn’s disease. David Wohl, MD, conducted a post hoc analysis of the COMBINE trial, which compared anti-TNF monotherapy to combination therapy with LD-MTX. The study concluded that the LD-MTX combination was not associated with … Read more

Education